Compare Merck & Co., Inc. (MRK) vs Spotify Technology (SPOT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Spotify Technology — how do they compare? Merck & Co., Inc. trades at $148.11 (market cap $366.28B), while Spotify Technology trades at $523.66 (market cap $108.68B). The key difference: Merck & Co., Inc. is far larger — about 3.4× Spotify Technology's market cap, and Merck & Co., Inc. pays a 2.29% dividend while Spotify Technology pays none. Which is the better fit depends on your goals.
| MRK | SPOT | |
|---|---|---|
Market Cap | $366.28B | $108.68B |
Sector | Health | Media |
52-Week High | $156.43 | $738.53 |
52-Week Low | $77.60 | $412.75 |
Enterprise Value | $413.04B | $98.31B |
Dividend Yield | 2.29% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $148.49, down 1.23% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $156.71. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending, and maintains a robust gross profit margin of 72.97%. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives amid a competitive pharmaceutical landscape.
The outlook for MRK is positive, driven by earnings momentum and strategic acquisitions, but risks include high valuation multiples like a P/E of 118.77 and regulatory pressures. Investors should weigh the company's solid cash flow and analyst support against potential market volatility and integration challenges from recent M&A activity.
Spotify (SPOT) trades at $528.64, down 2.54% on the day, but maintains a bullish technical outlook with strong fundamental momentum. The company reported record profitability with net income reaching $2.21 billion in 2025, representing a 12.87% margin, while revenue grew to $17.19 billion. Recent news highlights a $1.5 billion share repurchase authorization and ongoing subscriber growth, though Q2 2026 earnings missed expectations.
The stock presents a compelling growth story with expanding margins and positive cash flow generation, but faces valuation risks with a P/E of 28.61. Analyst consensus remains bullish with a $590.29 price target, representing 11.7% upside potential. Key risks include execution pressure to justify premium valuation and competitive threats in the audio streaming space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Spotify Technology
Spotify Technology S.A. provides music streaming services. The Company offers commercial-free music and ad-supported services to subscribers. Spotify Technology serves clients worldwide.
Read more on SPOT →
